Piper Jaffray Downgrades MannKind Corporation22percent
MannKind Corporation and its new inhalable insulin treatment, Afrezza, has been a widely talked about topic throughout 2015. During trials, Afrezza did very well and appeared to be a legitimate alternative form of care for people with diabetes that did not involve shots. From afar, this absolutely should like a product that will be able to do some real good and really be able to help those with diabetes. Unfortunately, sales of Afrezza were very slow coming out of the gate, leading bulls and bears to duke it out . . .
This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here
If you are subscribed and having an account error please clear cache and then cookies if that does not work email firstname.lastname@example.org and we will get back to you as quick as humanly possible